Credit John Carreyrou for his dogged pursuit of Theranos and the questionable regulatory and quality practices that have led to its death knell – and an assured steep descent from its $8B valuation high.
From his most recent WSJ article:
“In a statement posted on Theranos’s website late Wednesday, Ms. Holmes said: “We will return our undivided attention to our miniLab platform. Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.”
My Theranos reporting has evolved from avid defense in the period immediately following the publishing of Carreyrou’s scathing October 2014 WSJ article to, more recently, an inability to continue defending a company that gives us consistent WTF moments.
I’ll publish my detailed thoughts on the matter in the coming days with a full regulatory/ quality analysis but I’ll leave readers today with the following: